Skip to content

Study · Randomized controlled trial · n = 46 · 2020

2 results

Oxytocin Enhances an Amygdala Circuit Associated With Negative Symptoms in Schizophrenia: A Single-Dose, Placebo-Controlled, Crossover, Randomized Control Trial.

Abram SV, De Coster L, Roach BJ, Mueller BA, van Erp TGM, Calhoun VD, Preda A, Lim KO, Turner JA, Ford JM, Mathalon DH, Woolley JD

Schizophrenia bulletin1 Apr 2020Cited by 19 (Europe PMC)

PMID31595302 (opens in a new tab)PMCIDPMC7147578 (opens in a new tab)DOI10.1093/schbul/sbz091 (opens in a new tab)PepBankPUB-31595302
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialMechanism

    In people with schizophrenia, a single dose of intranasal oxytocin increased amygdala functional connectivity with the left middle temporal gyrus, superior temporal sulcus and angular gyrus compared with healthy controls.

    In plain wordsIn people with schizophrenia, one oxytocin dose raised connectivity between the amygdala and a temporal brain circuit, compared with healthy controls.

    Peptide
    Oxytocin
    Outcome
    IncreaseAmygdala resting-state connectivity with left MTG/STS/AngG in schizophrenia
    Study

    n = 46

    Comparator
    Healthy controls
    Outcome group
    Brain and neuronal activity · Nervous system and cognition
    Studied dose
    Dose not stated · intranasal · single doseAs given in this study (human).

    Source sentences

    Summary
    In sample 1, OT increased rsFC between the amygdala and left middle temporal gyrus, superior temporal sulcus, and angular gyrus (MTG/STS/AngG) in SZ compared to HC.
    1 context sentence
    Summary · context
    In sample 1, we used a double-blind, placebo-controlled, crossover design to test the effects of a single dose of intranasal OT on amygdala resting-state functional connectivity (rsFC) in SZ (n = 22) and healthy controls (HC, n = 24)
  2. 02HumanRandomized controlled trialMechanism

    In people with schizophrenia, more severe negative symptoms correlated with greater oxytocin-induced increases in amygdala connectivity.

    In plain wordsIn people with schizophrenia, more severe negative symptoms were linked to a larger oxytocin-induced rise in amygdala connectivity.

    Peptide
    Oxytocin
    Outcome
    IncreaseAssociation of negative symptoms with oxytocin-induced connectivity increase
    Study

    n = 22

    Outcome group
    Brain and neuronal activity · Nervous system and cognition
    Studied dose
    Dose not stated · intranasal · single doseAs given in this study (human).

    Source sentences

    Summary
    More severe negative symptoms correlated with less amygdala-to-left-MTG/STS/AngG connectivity on placebo and with greater OT-induced connectivity increases.
    1 context sentence
    Summary · context
    In sample 1, we used a double-blind, placebo-controlled, crossover design to test the effects of a single dose of intranasal OT on amygdala resting-state functional connectivity (rsFC) in SZ (n = 22) and healthy controls (HC, n = 24)

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:49 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.